LESTAURTINIB for B precursor type acute leukaemia: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 5 adverse event reports in the FDA FAERS database where LESTAURTINIB was used for B precursor type acute leukaemia.
Most Reported Side Effects for LESTAURTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Febrile neutropenia | 23 | 28.8% | 0 | 23 |
| Hypertriglyceridaemia | 13 | 16.3% | 10 | 5 |
| Clostridium difficile colitis | 10 | 12.5% | 0 | 10 |
| Death | 10 | 12.5% | 10 | 5 |
| Diarrhoea | 10 | 12.5% | 0 | 10 |
| Enterococcal infection | 9 | 11.3% | 0 | 9 |
| Sepsis | 9 | 11.3% | 0 | 9 |
| Bronchiolitis | 8 | 10.0% | 0 | 8 |
| Candida infection | 8 | 10.0% | 0 | 8 |
| Hypertension | 8 | 10.0% | 0 | 8 |
| Klebsiella infection | 8 | 10.0% | 0 | 8 |
| Otitis externa | 8 | 10.0% | 0 | 8 |
| Pulmonary oedema | 8 | 10.0% | 0 | 8 |
| Septic shock | 8 | 10.0% | 0 | 8 |
| Vomiting | 8 | 10.0% | 0 | 8 |
Other Indications for LESTAURTINIB
Other Drugs Used for B precursor type acute leukaemia
BLINATUMOMAB (1,791)
METHOTREXATE (1,067)
VINCRISTINE (977)
DEXAMETHASONE (662)
CYTARABINE (644)
CYCLOPHOSPHAMIDE (598)
PEGASPARGASE (531)
MERCAPTOPURINE (484)
DOXORUBICIN (331)
DAUNORUBICIN (274)